{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T15:39:37Z","timestamp":1793547577892,"version":"4.5.0"},"reference-count":31,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Japanese Association for Acute Medicine","award":["2018-08"],"award-info":[{"award-number":["2018-08"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Status epilepticus (SE) is an emergency condition for which rapid and secured cessation is crucial. Although fosphenytoin (FPHT) is recommended as a second-line treatment, levetiracetam (LEV) reportedly has similar efficacy, but higher safety. Therefore, we herein compared LEV with FPHT in adult SE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We initiated a multicentre randomised control trial in emergency departments with adult patients with convulsive SE. Diazepam was initially administered, followed intravenously by FPHT at 22.5\u2009mg\/kg or LEV at 1000\u20133000\u2009mg. The primary outcome was assigned as the seizure cessation rate within 30\u2009min of the administration of the study drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 176 adult patients with SE were enrolled (82 FPHT and 94 LEV), and 3 were excluded from the full analysis set. Seizure cessation rates within 30\u2009min were 83.8% (67\/80) in the FPHT group and 89.2% (83\/93) in the LEV group. The difference in these rates was 5.5% (95% CI \u22124.7 to 15.7, p=0.29). The non-inferiority of LEV to FPHT was confirmed with p&lt;0.001 by the Farrington-Manning test. No significant differences were observed in the seizure recurrence rate or intubation rate within 24\u2009hours. Serious adverse events developed in three patients in the FPHT group and none in the LEV group (p=0.061).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The efficacy of LEV was similar to that of FPHT for adult SE following the administration of diazepam. LEV may be recommended as a second-line treatment for SE along with phenytoin\/FPHT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>jRCTs031190160.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2022-329485","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T17:20:45Z","timestamp":1665163245000},"page":"42-48","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial"],"prefix":"10.1136","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8481-0294","authenticated-orcid":false,"given":"Kensuke","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiki","family":"Marushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Asami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Unemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Yonekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisei","family":"Hoshiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Matsumaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"2023051801102387000_94.1.42.1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2044.2001.02115.x"},{"key":"2023051801102387000_94.1.42.2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13121"},{"key":"2023051801102387000_94.1.42.3","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-19-07532.1997"},{"key":"2023051801102387000_94.1.42.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809173391202"},{"key":"2023051801102387000_94.1.42.5","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-012-9695-z"},{"key":"2023051801102387000_94.1.42.6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0733-8619(18)30033-1","article-title":"Status epilepticus","volume":"13","author":"Chang","year":"1995","journal-title":"Neurol Clin"},{"key":"2023051801102387000_94.1.42.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02917.x"},{"key":"2023051801102387000_94.1.42.8","doi-asserted-by":"publisher","DOI":"10.1179\/016164102101200834"},{"key":"2023051801102387000_94.1.42.9","doi-asserted-by":"publisher","DOI":"10.1197\/j.aem.2003.10.022"},{"key":"2023051801102387000_94.1.42.10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.seizure.2020.05.017","article-title":"Phenytoin versus fosphenytoin for second-line treatment of status epilepticus: propensity score matching analysis using a nationwide inpatient database","volume":"80","author":"Nakamura","year":"2020","journal-title":"Seizure"},{"key":"2023051801102387000_94.1.42.11","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00279.2011"},{"key":"2023051801102387000_94.1.42.12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1528-1167.2011.03237.x","article-title":"Established status epilepticus treatment trial (ESETT)","volume":"52 Suppl 8","author":"Cock","year":"2011","journal-title":"Epilepsia"},{"key":"2023051801102387000_94.1.42.13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.yebeh.2016.11.018","article-title":"Epilepsy treatment in adults and adolescents: expert opinion, 2016","volume":"69","author":"Shih","year":"2017","journal-title":"Epilepsy Behav"},{"key":"2023051801102387000_94.1.42.14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.04.013","article-title":"Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam--Pilot study","volume":"114","author":"Mundlamuri","year":"2015","journal-title":"Epilepsy Res"},{"key":"2023051801102387000_94.1.42.15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.seizure.2017.05.001","article-title":"Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: a prospective, randomized study","volume":"49","author":"Gujjar","year":"2017","journal-title":"Seizure"},{"key":"2023051801102387000_94.1.42.16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jocn.2014.12.013","article-title":"Levetiracetam versus phenytoin in management of status epilepticus","volume":"22","author":"Chakravarthi","year":"2015","journal-title":"J Clin Neurosci"},{"key":"2023051801102387000_94.1.42.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30724-X"},{"key":"2023051801102387000_94.1.42.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30722-6"},{"key":"2023051801102387000_94.1.42.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905795"},{"key":"2023051801102387000_94.1.42.20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2176\/nmc.oa.2019-0225","article-title":"Changes in real-world practice patterns of antiepileptic drugs for status epilepticus: a nationwide observational study in Japan","volume":"60","author":"Nakamura","year":"2020","journal-title":"Neurol Med Chir"},{"key":"2023051801102387000_94.1.42.21","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00615","article-title":"Levetiracetam vs. fosphenytoin for second-line treatment of status epilepticus: propensity score matching analysis using a nationwide inpatient database","volume":"11","author":"Nakamura","year":"2020","journal-title":"Front Neurol"},{"key":"2023051801102387000_94.1.42.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05269-7","article-title":"Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-inferiority designed randomized control trial","volume":"22","author":"Nakamura","year":"2021","journal-title":"Trials"},{"key":"2023051801102387000_94.1.42.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb02000.x"},{"key":"2023051801102387000_94.1.42.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70374-X"},{"key":"2023051801102387000_94.1.42.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002736","article-title":"The eye response test alone is sufficient to predict stroke outcome--reintroduction of Japan Coma Scale: a cohort study","volume":"3","author":"Shigematsu","year":"2013","journal-title":"BMJ Open"},{"key":"2023051801102387000_94.1.42.26","unstructured":"Japanese society of neurology . Japanese epilepsy clinical practice guideline."},{"key":"2023051801102387000_94.1.42.27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001940"},{"key":"2023051801102387000_94.1.42.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-6227-2"},{"key":"2023051801102387000_94.1.42.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00296-3"},{"key":"2023051801102387000_94.1.42.30","unstructured":"NICE guidance epilepsies: diagnosis and management. Available: https:\/\/www.nice.org.uk\/Guidance\/cg137"},{"key":"2023051801102387000_94.1.42.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30611-5"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2022-329485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:14:48Z","timestamp":1684397688000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2022-329485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,14]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/jnnp-2022-329485"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2022-329485","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}